In the dynamic field of cancer research, understanding the mechanisms of DNA repair and identifying novel therapeutic targets are paramount. Among the key molecules gaining significant attention is Veliparib, also known by its development code ABT-888. As a leading manufacturer and supplier in China, we are committed to providing high-quality research chemicals like Veliparib to facilitate groundbreaking studies.

Veliparib is a potent, orally bioavailable inhibitor of Poly(ADP-ribose) polymerase (PARP) enzymes, specifically targeting PARP-1 and PARP-2. These enzymes are critical in cellular responses to DNA damage, particularly in repairing single-strand breaks. By inhibiting PARP, Veliparib prevents the efficient repair of DNA lesions, leading to an accumulation of unrepaired DNA damage in cancer cells. This mechanism is especially effective in cancer cells that already have defects in other DNA repair pathways, such as those with BRCA mutations, a concept known as synthetic lethality.

The primary utility of Veliparib in research lies in its ability to potentiate the effects of DNA-damaging agents. This includes conventional chemotherapy drugs like temozolomide, carboplatin, and paclitaxel, as well as radiation therapy. Researchers utilize Veliparib to investigate how combining these treatments can lead to enhanced anti-tumor activity, increased apoptosis (programmed cell death), and improved overall treatment outcomes. This makes Veliparib an indispensable tool for those looking to buy and experiment with combination cancer therapies.

For procurement managers and R&D scientists, sourcing reliable and high-purity Veliparib is crucial. As a dedicated supplier from China, we ensure that our Veliparib meets stringent quality standards, typically offering >98% purity. Our commitment extends to providing a stable supply chain, competitive pricing, and responsive customer service to meet the demands of your research projects. If you are looking to purchase Veliparib for your laboratory, consider us as your trusted manufacturer and supplier.

Exploring the biological activity of Veliparib involves understanding its interactions with cellular pathways. Studies have shown that beyond PARP inhibition, Veliparib can also influence autophagy and apoptosis, further contributing to its anti-cancer potential. This multifaceted action makes it a subject of extensive research in various cancer types, including ovarian, breast, and lung cancers. Understanding the specific research applications and the chemical properties of Veliparib is key for effective utilization.

When considering the purchase of Veliparib, it's essential to partner with a reputable manufacturer. Our aim is to be that partner, providing detailed technical data, CAS number information (912444-00-9), and consistent product quality. We encourage you to reach out for a quote or to discuss bulk purchase options. By supplying high-quality Veliparib, we support the scientific community's efforts in advancing cancer treatment strategies.